06.06.2013 Views

Donepezil, rivastigmine, galantamine and memantine for ...

Donepezil, rivastigmine, galantamine and memantine for ...

Donepezil, rivastigmine, galantamine and memantine for ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

52<br />

Clinical effectiveness<br />

This appeared generally to be related to higher<br />

doses of <strong>rivastigmine</strong>, but, it was not tested <strong>for</strong><br />

statistical significance in the two published trials.<br />

[Commercial/academic confidential in<strong>for</strong>mation<br />

removed] Two trials showed no difference in the<br />

rates of withdrawals <strong>and</strong> one 57 demonstrated a<br />

higher proportion in the placebo group, but these<br />

were not tested <strong>for</strong> statistical significance. Very few<br />

deaths were reported. All data relating to<br />

withdrawals <strong>and</strong> deaths can be found <strong>for</strong> the<br />

individual studies in Appendix 8.<br />

Summary<br />

● Four published RCTs on the effectiveness of<br />

<strong>rivastigmine</strong> met the inclusion criteria <strong>for</strong> this<br />

review. All four trials were sponsored by the<br />

manufacturer. The quality of reporting was<br />

generally poor <strong>for</strong> two of these. None of the<br />

trials lasted longer than 26 weeks. Only two of<br />

the trials reported an adequate method of<br />

r<strong>and</strong>omisation, <strong>and</strong> only one of these clearly<br />

reported concealment of allocation. The other<br />

three may there<strong>for</strong>e have been subject to<br />

selection bias, which would affect interpretation<br />

of the results. Withdrawals were not adequately<br />

described by two of the trials, <strong>and</strong> attrition bias<br />

may there<strong>for</strong>e affect the results of these. None<br />

of the trials reported assessor blinding<br />

adequately, so measurement bias may need to<br />

be taken into consideration when discussing the<br />

trials’ findings.<br />

● Two unpublished studies were included in the<br />

review. [Commercial/academic confidential<br />

in<strong>for</strong>mation removed]<br />

● Statistically significant differences between the<br />

6–12 mg/day treatment groups (mean dose<br />

~10 mg/day) <strong>and</strong> placebo were reported by two<br />

of three published trials which reported ADAScog<br />

<strong>and</strong> MMSE. No statistically significant<br />

effects were seen in the low-dose treatment<br />

groups in these studies. Forette <strong>and</strong> colleagues 60<br />

found that participants receiving twice daily<br />

doses of <strong>rivastigmine</strong> scored statistically<br />

significantly better on the Wechsler logical<br />

memory test than did those receiving the drug<br />

three times daily. However, sample sizes were<br />

very low (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!